Scottsdale, Arizona
Alternative Colon Cancer Treatment & Integrative Colorectal Cancer Care in Scottsdale, Arizona
A More Individualized Approach to Colon Cancer Care
A diagnosis of colon or colorectal cancer can change everything in a matter of days.
Suddenly there are pathology reports to understand, scans to review, treatment decisions to make and unfamiliar terms such as MSI, MMR, KRAS, BRAF, chemotherapy, immunotherapy and targeted therapy entering every conversation.
And for many patients, another question quickly follows:
Are there additional treatment options that can be considered alongside conventional cancer care?
At Sunridge Medical in Scottsdale, Arizona, we provide individualized integrative and alternative cancer care for people with colon and colorectal cancer at many different points in their cancer journey—from a recent diagnosis to recurrent, metastatic or heavily pretreated disease.
Our approach is not based on the idea that every patient with colon cancer should receive the same protocol.
Instead, treatment planning begins by looking closely at the individual patient: the exact diagnosis, stage of disease, pathology, molecular characteristics of the tumor, treatments already received, current medications, nutritional status, treatment tolerance, overall health and personal goals.
The objective is to build a treatment strategy around the patient—not simply around the name of the cancer.
Terminology matters
What Does “Alternative Colon Cancer Treatment” Actually Mean?
Patients searching online frequently use terms such as alternative colon cancer treatment, natural colon cancer treatment, holistic cancer treatment and alternative treatments for Stage 4 colon cancer.
These terms, however, do not all mean the same thing.
Complementary cancer care refers to therapies used alongside conventional medical treatment.
Alternative cancer treatment generally refers to treatment used instead of conventional treatment.
Integrative oncology combines conventional cancer care with complementary approaches selected according to the patient’s individual circumstances and the available scientific evidence.1
At Sunridge Medical, patients may come to us because they want additional supportive options during conventional treatment, because they are experiencing difficult treatment-related symptoms, because their disease has progressed, or because they are investigating approaches outside conventional oncology.
Whatever brings a patient to our clinic, one principle is important:
The evidence, potential benefits, limitations, safety issues and possible interactions all matter.
The basics
Understanding Colon and Colorectal Cancer
Colon cancer begins in the colon, which makes up most of the large intestine. Rectal cancer begins in the rectum, the final portion of the large intestine before the anus.
Together, cancers of the colon and rectum are commonly referred to as colorectal cancer.
Most colorectal cancers are adenocarcinomas that arise from gland-forming cells in the inner lining of the colon or rectum. Some begin within precancerous polyps that accumulate molecular changes over time.
Colon and rectal cancers share many biological features, but they are not always treated in exactly the same way. The location of a rectal tumor, for example, can make radiation therapy and preoperative treatment particularly important, whereas radiation is used much less frequently for typical colon cancer.
That is one reason an accurate diagnosis matters before considering any conventional, complementary or alternative treatment strategy.
Colorectal Cancer Is Changing
Colorectal cancer remains one of the most important cancers in the United States.
The American Cancer Society estimates approximately 158,850 new colorectal cancer diagnoses and 55,230 deaths in the United States in 2026.2
It is also no longer accurate to think of colorectal cancer as primarily a disease of older adults.
Nearly 45% of new colorectal cancer diagnoses now occur in people younger than 65, and incidence has been increasing particularly among younger generations.2
This changing epidemiology is one of the reasons modern screening recommendations begin earlier than they once did.
Colon Cancer Symptoms: What Should You Watch For?
Early colorectal cancer may cause no obvious symptoms, which is one reason screening is so important.
When symptoms do occur, they may include:
- Blood in or on the stool
- Rectal bleeding
- Persistent change in bowel habits
- New constipation or diarrhea
- Narrowing or change in the appearance of stools
- A feeling that the bowel does not empty completely
- Persistent abdominal discomfort, cramping or bloating
- Unexplained iron-deficiency anemia
- Fatigue or weakness
- Unintentional weight loss
- Reduced appetite
- Abdominal or pelvic pain
These symptoms do not automatically mean cancer. Hemorrhoids, inflammatory bowel disease, infections and many other gastrointestinal conditions can cause similar symptoms.
Persistent symptoms—especially unexplained bleeding or iron-deficiency anemia—deserve medical evaluation.
Risk Factors for Colon and Colorectal Cancer
No single risk factor explains every case of colorectal cancer.
Risk can be influenced by combinations of genetics, age, medical history, lifestyle and environmental factors.
Important established risk factors include:
- Increasing age
- Personal history of colorectal polyps or colorectal cancer
- Family history of colorectal cancer
- Lynch syndrome and other inherited cancer-predisposition syndromes
- Familial adenomatous polyposis
- Long-standing inflammatory bowel disease
- Tobacco use
- Higher alcohol intake
- Excess body weight
- Physical inactivity
- Certain dietary patterns
Having a risk factor does not mean that a person will develop cancer, and many people diagnosed with colorectal cancer do not have an obvious explanation for why it developed.
Prevention & detection
Colorectal Cancer Screening Can Prevent Cancer, Not Just Find It Earlier
One of the most important changes from older colorectal-cancer guidance is the recommended age for screening.
The American Cancer Society recommends that average-risk adults begin regular colorectal-cancer screening at age 45.3
Screening options can include stool-based testing, colonoscopy and other visual examinations of the colon. The appropriate test and interval depend on the patient’s risk and previous findings.
Colonoscopy has an additional advantage: precancerous polyps can frequently be removed before they progress to invasive cancer.
Patients with a family history of colorectal cancer, previous advanced polyps, inflammatory bowel disease or hereditary cancer syndromes may need to begin screening earlier or follow a different surveillance schedule.
Individualized planning
Colon Cancer Treatment Should Be Based on More Than the Word “Cancer”
Two patients can both be told they have Stage IV colon cancer and still have very different diseases.
Where did the cancer originate?
Right-sided and left-sided colon cancers can differ biologically.
Has the cancer spread?
If so, is disease limited to the liver or lungs, or is it more widely metastatic?
Can all visible disease potentially be removed or treated locally?
Selected patients with limited metastatic disease may have very different treatment options from patients with widespread metastatic disease.
What does the pathology show?
Tumor grade, lymphovascular invasion, perineural invasion, lymph-node involvement and surgical margins can all affect treatment planning.
What molecular alterations are present?
Modern colorectal oncology increasingly depends upon molecular testing.
What treatments has the patient already received?
A newly diagnosed patient is different from someone whose disease has progressed through multiple systemic therapies.
What is the patient's overall health and treatment tolerance?
Kidney function, liver function, blood counts, nutritional status, gastrointestinal function, neuropathy, weight loss and other health conditions can influence both conventional and integrative treatment planning.
This is the foundation of individualized cancer care.
Precision oncology
The Importance of Molecular Testing in Colorectal Cancer
One of the most significant advances in colorectal-cancer treatment is the ability to identify molecular characteristics that can influence treatment.
Depending upon the patient’s stage and clinical situation, testing may evaluate biomarkers such as:
Mismatch Repair and Microsatellite Instability — MMR/MSI
Tumors that are mismatch-repair deficient (dMMR) or microsatellite-instability high (MSI-H) can respond differently to immunotherapy.
In metastatic MSI-H/dMMR colorectal cancer, immune-checkpoint therapy has fundamentally changed treatment for appropriate patients.4
KRAS and NRAS
RAS mutations can affect whether certain EGFR-targeted drugs are likely to help.
Knowing RAS status may also be relevant when evaluating emerging or investigational treatment strategies.
BRAF
The BRAF V600E mutation identifies a biologically distinct subgroup of colorectal cancer for which specific targeted combinations are available.5
Other Potentially Actionable Alterations
Depending upon the clinical situation, oncologists may also evaluate abnormalities involving HER2, KRAS G12C, NTRK and other molecular targets.
Not every biomarker has an effective therapy, and not every targeted therapy is appropriate for every stage of cancer.
But understanding the molecular profile can prevent a patient from treating all colorectal cancers as though they were identical.
Established treatment
Conventional Treatment for Colon Cancer
A comprehensive discussion of alternative colon cancer treatment should also explain conventional treatment accurately.
The major conventional treatment options include:
Surgery
For many localized colon cancers, surgery remains the central potentially curative treatment.
The tumor and an appropriate section of surrounding colon are removed, along with regional lymph nodes for pathological evaluation.
Chemotherapy
Chemotherapy may be recommended after surgery for selected Stage II cancers and commonly for Stage III disease.
It is also a central treatment for many patients with metastatic colorectal cancer.
Common systemic regimens can contain drugs such as fluoropyrimidines, oxaliplatin and irinotecan, sometimes combined with biologic or targeted therapies.
Radiation Therapy
Radiation has a particularly important role in many rectal cancers.
It is used much less routinely for colon cancer but can be appropriate in selected circumstances, including palliation or certain locally advanced tumors.
Targeted Therapy
Targeted treatments may be selected according to tumor biology, treatment history and molecular findings.
Immunotherapy
Immunotherapy can produce important and sometimes durable responses in appropriately selected colorectal cancers, particularly tumors with MSI-H/dMMR biology.4
Local Treatment of Metastatic Disease
Selected patients with disease limited to sites such as the liver or lung may be candidates for surgery, ablation, radiation or other localized approaches.
Stage IV colorectal cancer is not one single clinical situation.
A patient with one potentially resectable liver metastasis and a patient with widespread metastatic disease should not automatically receive the same treatment strategy.
Integrative oncology
Where Integrative Colon Cancer Care May Fit
Integrative oncology should not simply mean adding as many therapies as possible.
More treatment is not necessarily better treatment.
A thoughtful integrative plan considers what a patient is already receiving, what the scientific evidence suggests, whether therapies could interact and what specific goal each intervention is intended to accomplish.
Potential goals of integrative care may include:
- Supporting nutritional status
- Maintaining strength and physical function
- Helping patients tolerate treatment
- Addressing treatment-related symptoms
- Supporting hydration and nutrient deficiencies when clinically appropriate
- Managing fatigue
- Addressing sleep and stress
- Supporting quality of life
- Evaluating evidence-informed complementary interventions
- Reviewing potential interactions between natural compounds and conventional medications
- Helping patients understand experimental or emerging therapies
- Developing a plan for patients seeking additional options after progression
The exact plan should be individualized.
Evidence review
Natural and Alternative Colon Cancer Treatments: What Does the Research Actually Show?
Patients deserve something more useful than a list of supplements described as “cancer killers.”
Different natural compounds have dramatically different levels of evidence.
Some have been studied only in cells.
Others have animal research.
A much smaller group has been evaluated in human cancer patients.
And even a human study does not automatically establish that a therapy improves survival or controls cancer.
At Sunridge Medical, we believe those distinctions matter.
High-Dose Intravenous Vitamin C and Colorectal Cancer
Intravenous vitamin C has attracted substantial interest in integrative oncology because intravenous administration can achieve blood concentrations that cannot be reached with ordinary oral supplementation.
Importantly, IV vitamin C has actually been studied in a large randomized colorectal-cancer trial.
The phase III VITALITY trial evaluated high-dose intravenous vitamin C combined with first-line chemotherapy in patients with metastatic colorectal cancer.6
The study did not demonstrate a statistically significant progression-free-survival advantage for IV vitamin C in the overall study population.
However, a prespecified subgroup of patients with RAS-mutated tumors showed a potential progression-free-survival signal that researchers considered worthy of further investigation.6
It also means it is reasonable for researchers and integrative physicians to continue examining where pharmacologic vitamin C may or may not have a role.
Individual safety considerations—including renal function, G6PD status, medications and the patient’s treatment regimen—must be evaluated.
Curcumin and Colorectal Cancer
Curcumin is one of the principal bioactive components of turmeric and has been extensively studied in laboratory models involving inflammation, cell signaling and cancer biology.
Human evidence is much more limited.
A randomized phase IIa study evaluated curcumin given with FOLFOX chemotherapy in patients with metastatic colorectal cancer and concluded that the combination was feasible and tolerable in the studied population.7
That is useful clinical information.
Resveratrol and Colorectal Cancer
Resveratrol is a naturally occurring polyphenol that has been studied extensively for its effects on cell signaling, oxidative stress and cancer-related pathways.
Unlike many natural compounds, resveratrol has also been administered to patients with colorectal cancer before surgery.
In a small human study, researchers demonstrated that resveratrol and its metabolites reached colorectal tissue and observed a modest change in a tumor-proliferation biomarker.8
Quercetin and Colorectal Cancer
Quercetin is a flavonoid found naturally in foods such as onions, apples and certain vegetables.
Laboratory research has investigated effects involving oxidative signaling, apoptosis, inflammation, cell proliferation and pathways relevant to colorectal cancer.
However, the evidence supporting quercetin as a treatment for human colorectal cancer remains predominantly preclinical.9
Lifestyle medicine
Exercise Is Not a “Soft” Intervention
One of the most interesting recent developments in colorectal-cancer supportive care did not involve an expensive drug or supplement.
It involved exercise.
The randomized CHALLENGE trial, published in 2025, evaluated a structured three-year exercise program following adjuvant chemotherapy in patients with resected colon cancer.10
At five years, disease-free survival was approximately 80.3% in the structured-exercise group compared with 73.9% in the health-education group.10
This does not mean exercise replaces surgery or chemotherapy.
It means that lifestyle medicine deserves to be treated seriously as part of comprehensive cancer care.
An appropriate exercise program may also support cardiovascular fitness, muscle mass, functional capacity, mood and overall quality of life.
Programs should be adjusted for the patient’s condition, treatment status, anemia, neuropathy, surgical recovery, bone disease and other medical limitations.
Nutrition During Colon Cancer Treatment
There is no single “colon cancer diet” proven to cure colorectal cancer.
Nutrition should instead be personalized around the patient’s clinical needs.
Those needs can change dramatically during treatment.
A patient recovering from bowel surgery may need a very different diet from a patient several months after treatment.
A person experiencing diarrhea from treatment may temporarily need very different foods from someone working on long-term metabolic and cardiovascular health.
Important considerations can include:
- Adequate protein and calorie intake
- Preservation of lean body mass
- Hydration and electrolyte status
- Iron, B12, folate and other deficiencies when present
- Bowel function
- Treatment-related diarrhea or constipation
- Nausea and appetite loss
- Blood glucose and metabolic health
- Food tolerance after surgery
- Maintaining a healthy body weight
- Long-term dietary quality
Cancer-related weight loss and loss of muscle mass should not automatically be interpreted as desirable simply because a patient is trying to eat a “clean” diet.
During active cancer treatment, maintaining adequate nutrition can be critically important.
Integrative Care During Chemotherapy
Many patients come to Sunridge Medical because they are receiving conventional chemotherapy but want additional support.
That is a fundamentally different situation from simply trying to replace chemotherapy.
A patient receiving FOLFOX, CAPOX, FOLFIRI or another regimen may be dealing with issues such as:
- Fatigue
- Neuropathy
- Nausea
- Changes in appetite
- Diarrhea or constipation
- Weight loss
- Dehydration
- Blood-count changes
- Sleep disruption
- Anxiety
- Reduced physical conditioning
An integrative plan should be designed around the patient’s specific regimen and laboratory findings.
It should also be coordinated carefully enough that a supportive intervention does not unnecessarily interfere with a treatment that is helping control the disease.
Advanced disease
Integrative Care for Stage 4 and Metastatic Colon Cancer
A Stage IV diagnosis can feel as though every decision has suddenly become urgent.
But Stage IV disease covers a very broad range of circumstances.
Before assuming that conventional options have been exhausted, important questions include:
Has the pathology been reviewed?
Has comprehensive molecular testing been performed when appropriate?
Is the tumor MSI-H or mismatch-repair deficient?
What are the KRAS, NRAS and BRAF results?
Are there other potentially actionable alterations?
Where exactly has the cancer spread?
Could limited metastatic disease be treated locally?
Has the case been evaluated by physicians experienced with liver or lung metastases if those sites are involved?
Are relevant clinical trials available?
What treatments have already been tried, at what doses, and why were they stopped?
These questions can materially change the options available.
For patients whose disease has progressed despite several therapies, integrative care may focus both on exploring additional treatment possibilities and on preserving strength, function, nutrition and quality of life.
What If Conventional Treatment Has Stopped Working?
Progression does not automatically mean there are no further decisions to make.
A thorough reassessment can include:
Review the Original Diagnosis
Pathology can sometimes deserve re-review, particularly in complicated or unusual cases.
Reassess the Current Extent of Disease
Current imaging may reveal a different treatment opportunity than was present earlier.
Review Molecular Testing
Tumor biology can affect targeted treatment and immunotherapy options.
Review Previous Treatment
What drugs were used?
How long did they work?
Why were they discontinued?
Was treatment stopped because of progression, toxicity or another reason?
Consider Clinical Trials
Clinical trials may provide access to treatments that are not yet routinely available.
Address the Patient, Not Only the Scan
Pain, nutrition, muscle loss, sleep, gastrointestinal function, emotional health and treatment tolerance remain important even when cancer is advanced.
Our approach
The Sunridge Medical Approach to Colon Cancer
At Sunridge Medical, the first question is not simply:
“What do we give someone with colon cancer?”
The better question is:
“What does this particular patient need, and what does the evidence actually support?”
An individualized evaluation may review:
- Diagnosis and pathology
- Stage of cancer
- Previous surgery
- Previous chemotherapy and radiation
- Current imaging
- Molecular and biomarker results
- Blood work
- Kidney and liver function
- Current medications
- Supplements and complementary therapies already being used
- Nutritional status
- Treatment-related symptoms
- Physical function
- Other medical conditions
- Patient priorities and treatment goals
From there, physicians can determine which available conventional, integrative or complementary strategies warrant consideration and which do not.
Not every treatment offered at Sunridge Medical is appropriate for every colon-cancer patient.
Evidence before hype
A Different Standard for Alternative Cancer Information
There is enormous interest in natural and alternative cancer therapies.
There is also enormous misinformation.
Patients may read that a substance “kills 90% of colon cancer cells” without being told that the experiment occurred in a laboratory dish.
They may see an animal study described as though it were a human clinical trial.
They may see one patient’s dramatic story presented as proof of a treatment.
We believe patients deserve a clearer standard.
When evaluating a therapy, we want to know:
Has it been studied in humans?
Laboratory and animal research can identify promising ideas, but it cannot prove that a treatment works in people.
What was the goal of the study?
A therapy that improves nausea should not automatically be described as a therapy that controls cancer.
Was survival or tumor response actually measured?
Changes in laboratory biomarkers can be scientifically interesting without proving a meaningful clinical benefit.
How large was the study?
A study involving 10 or 20 patients provides a different level of evidence from a randomized trial involving hundreds of patients.
Has the result been reproduced?
One intriguing study should usually generate more research—not absolute conclusions.
This evidence-based approach allows us to remain open to emerging therapies without confusing possibility with proof.
Questions to Ask Any Alternative or Integrative Cancer Clinic
Before committing to treatment anywhere, patients should feel comfortable asking:
What evidence supports the treatment being recommended for my particular cancer?
Is that evidence from human clinical trials or primarily laboratory research?
What is the specific purpose of the therapy?
Is it intended to treat the tumor, support treatment tolerance, address a symptom or improve nutritional status?
What are the known risks?
Could it interact with my chemotherapy, immunotherapy, anticoagulants or other medications?
How will we determine whether it is helping?
Will you review my pathology, imaging and molecular testing?
Will you work with my conventional oncology team?
What will the treatment cost?
Patients deserve understandable answers to these questions.
Why Patients Travel to Sunridge Medical in Scottsdale, Arizona
Patients seek care at Sunridge Medical from Arizona, throughout the United States and internationally.
Our Scottsdale location allows patients to receive individualized outpatient integrative care while remaining connected to their existing oncology team when appropriate.
Patients may come to us:
- Immediately after diagnosis
- Before conventional treatment begins
- While receiving chemotherapy or radiation
- During recovery after surgery
- After cancer recurrence
- With metastatic or Stage IV disease
- After experiencing significant treatment side effects
- After progression despite conventional therapies
- When seeking another perspective on their available options
The starting point is an individual evaluation—not a predetermined colon-cancer protocol.
Your Diagnosis Is the Beginning of the Conversation—not the End of It
A colorectal-cancer diagnosis can create a tremendous amount of fear.
It can also create pressure to make major treatment decisions quickly.
Information matters.
So does understanding what is known, what is uncertain and what options are genuinely available in your individual situation.
At Sunridge Medical, our goal is to help patients look at the broader picture and develop a personalized approach to care based upon their diagnosis, previous treatment, current health and goals.
If you are newly diagnosed, currently receiving treatment, facing recurrence or progression, or simply want to understand what integrative and alternative colon cancer treatment options may exist, our Patient Care Team can help you take the next step.
Speak With the Sunridge Medical Patient Care Team
Sunridge Medical • Scottsdale, Arizona
Request a consultation to have your case reviewed.
Frequently asked questions
Frequently Asked Questions About Alternative Colon Cancer Treatment
Can colon cancer be treated naturally?
Yes, natural therapy, although it has not been established as a universal replacement for surgery, chemotherapy, targeted therapy, immunotherapy or other medically indicated colorectal-cancer treatment, can have tremendous benefits in treating patients with cancer.
Some natural compounds have been studied as complementary therapies, but evidence varies widely. Some have human clinical data, while others remain supported mainly by laboratory studies.
The appropriate approach depends upon the patient’s stage, tumor biology, prior treatment and overall health.
Can Stage 4 colon cancer be treated?
Stage IV colorectal cancer is treatable, although treatment goals and prognosis vary considerably.
Systemic therapy, immunotherapy in selected tumors, targeted therapy, surgery or local treatment of metastases may all be considered depending upon the individual case.
Selected patients with limited metastatic disease can have very different treatment opportunities from those with widespread disease.
Does Sunridge Medical treat patients who are receiving chemotherapy?
Integrative care can be considered for patients undergoing conventional treatment.
Any complementary therapy should be evaluated in the context of the exact chemotherapy regimen and the patient’s medications, laboratory results, kidney and liver function and treatment-related symptoms.
Can IV vitamin C be used for colon cancer?
High-dose intravenous vitamin C has been investigated in metastatic colorectal cancer, including in a randomized phase III clinical trial.6
Whether it is reasonable to consider in a particular integrative plan requires individualized medical evaluation.
Does curcumin treat colon cancer?
Curcumin has extensive laboratory research and limited human clinical data.
A small randomized phase IIa study found that curcumin could be administered as an adjunct to FOLFOX in patients with metastatic colorectal cancer.7
That study does not establish curcumin as a stand-alone treatment or prove a survival benefit.
What about quercetin or resveratrol?
Both compounds have interesting biological research related to colorectal cancer.
Neither should be presented to patients as a proven replacement for established colorectal-cancer treatment.
Should every colon cancer patient have genetic or molecular testing?
Not every test is necessary for every patient, but molecular testing has become increasingly important in colorectal cancer.
MMR/MSI status has particularly important treatment and hereditary implications, and patients with advanced disease frequently undergo additional molecular testing that can include RAS and BRAF.
The appropriate testing depends upon the patient’s disease and clinical circumstances.
Is colon cancer the same as rectal cancer?
They are closely related and are collectively called colorectal cancer, but they are not identical.
Tumor location can substantially influence treatment. Radiation and preoperative treatment, for example, play a larger role in many rectal cancers than in typical colon cancers.
Can integrative medicine reduce cancer-treatment side effects?
Some integrative interventions have evidence for helping specific symptoms and quality-of-life concerns in people with cancer.11
The benefit depends upon the intervention and the symptom being treated.
An intervention shown to improve anxiety, pain or nausea should not automatically be assumed to treat the cancer itself.
What should I bring to my first consultation?
Having the most complete record possible can make the consultation more useful.
Relevant information can include pathology reports, operative reports, recent CT/MRI/PET imaging and reports, oncology notes, chemotherapy history, radiation records, molecular or genomic testing, recent laboratory results, medication and supplement lists, and a brief timeline of your cancer treatment.
Sources
References
- National Cancer Institute. Complementary and Alternative Medicine (CAM). Definitions and overview of complementary, alternative and integrative medicine.
- Siegel RL, Wagle NS, Star J, Kratzer TB, Smith RA, Jemal A. Colorectal Cancer Statistics, 2026. CA: A Cancer Journal for Clinicians. 2026;76(2):e70067. doi:10.3322/caac.70067.
- American Cancer Society. American Cancer Society Guideline for Colorectal Cancer Screening. Updated 2026. Average-risk adults should begin regular colorectal cancer screening at age 45.
- André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. New England Journal of Medicine. 2020;383:2207-2218. doi:10.1056/NEJMoa2017699.
- U.S. Food and Drug Administration. FDA Grants Traditional Approval to Encorafenib for Metastatic Colorectal Cancer With a BRAF V600E Mutation. February 24, 2026.
- Wang F, et al. A Randomized, Open-Label, Multicenter, Phase III Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer: The VITALITY Study. Clinical Cancer Research. 2022;28(19):4232-4239. doi:10.1158/1078-0432.CCR-22-0655.
- Howells LM, Iwuji COO, Irving GRB, et al. Curcumin Combined With FOLFOX Chemotherapy Is Safe and Tolerable in Patients With Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. Journal of Nutrition. 2019;149(7):1133-1139. doi:10.1093/jn/nxz029.
- Patel KR, Brown VA, Jones DJL, et al. Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients. Cancer Research. 2010;70(19):7392-7399. doi:10.1158/0008-5472.CAN-10-2027.
- Duan X, Zhang L, Liu F. The Potential Value of Quercetin for Colorectal Cancer: A Systematic Review and a Meta-Analysis of Preclinical Studies. Frontiers in Pharmacology. 2025;16:1642957. doi:10.3389/fphar.2025.1642957.
- Courneya KS, et al. Structured Exercise After Adjuvant Chemotherapy for Colon Cancer. New England Journal of Medicine. 2025;393:13-25. doi:10.1056/NEJMoa2502760.
- Carlson LE, Ismaila N, Addington EL, et al. Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline. Journal of Clinical Oncology. 2023;41(28):4562-4591. doi:10.1200/JCO.23.00857.
Medical Information Disclaimer
This information is provided for general education and is not a substitute for individualized medical advice, diagnosis or treatment. Cancer treatment decisions should be made after review of the patient’s specific diagnosis, stage, pathology, molecular findings, medical history and treatment options.
Individual treatment recommendations, eligibility, risks and potential interactions require medical evaluation.
